Deferasirox
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
Deferasirox: From Beta-Thalassemia to HIV Infectious Disease
One-Sentence Summary
Deferasirox is an iron chelator originally used for iron overload in beta-thalassemia and related hemoglobin disorders. The TxGNN model predicts it may be effective for HIV infectious disease, but there are currently no registered clinical trials and only 2 publications (one drug overview and one preclinical study), so this remains a research question rather than an established direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Beta-thalassemia and related hemoglobinopathies (including hereditary persistence of fetal hemoglobin and beta-thalassemia intermedia) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 0.9940 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, deferasirox is an iron chelator. Its efficacy in managing iron overload in beta-thalassemia is established, and mechanistically it may be relevant to HIV because iron status can influence viral replication.
The main supporting study is a 2021 preclinical paper (PMID 34550543). It reports that iron inside endolysosomes restricts Tat-mediated HIV-1 LTR transactivation by increasing Tat oligomerization and β-catenin expression. This links iron homeostasis to HIV-1 transcription.
However, this is mechanistic work and does not show that chelation with deferasirox treats HIV. Iron depletion could plausibly change viral replication in either direction, so the direction of effect is unresolved. The other publication (PMID 16529348) is a general new-drug overview that covers deferasirox approval and contains no HIV-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34550543 | 2021 | Preclinical/Mechanistic | Journal of Neurovirology | Endolysosomal iron restricts HIV-1 Tat-mediated LTR transactivation by increasing Tat oligomerization and β-catenin expression |
| 16529348 | 2006 | Review | Journal of the American Pharmacists Association | Overview of new drugs including deferasirox; no HIV-specific evidence |
Canada Market Information
Deferasirox has 20 valid single-ingredient authorizations in Canada. Dosage form and approved indication text were not available for these products. Main authorizations:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02287420 | EXJADE | Not available | Not available |
| 02287439 | EXJADE | Not available | Not available |
| 02287447 | EXJADE | Not available | Not available |
| 02452227 | JADENU | Not available | Not available |
| 02452235 | JADENU | Not available | Not available |
Generic versions are also marketed under the Apo, Sandoz, Taro, PMS and Auro names.
Safety Considerations
Contraindication-related conditions (from a knowledge graph, not label text):
- Liver and kidney: liver failure, liver disease, cirrhosis of liver, kidney disease, impaired renal function disease, gallbladder disease
- Blood: thrombocytopenia, neutropenia (including several congenital forms), agranulocytosis, anemia, cyclic hematopoiesis
- Bilirubin: hyperbilirubinemia, Gilbert syndrome
- Other: active peptic ulcer disease, ocular hypertension, multiple organ dysfunction syndrome, cancer
Drug Interactions: 100 interactions were found; the first 20 reviewed include these main ones.
- Major: corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone), amphotericin B (including lipid, liposomal and cholesteryl sulfate formulations), acetylsalicylic acid, mesalazine, balsalazide
- Moderate: rabeprazole, pioglitazone, alosetron, aprepitant, clarithromycin, saxagliptin, aluminum hydroxide, cisapride, dexfenfluramine
Label warnings and contraindications from the Health Canada package insert were not available. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but evidence is limited to one preclinical mechanistic study and a general drug overview, with no clinical trials. The direction of iron’s effect on HIV replication is unresolved. Deferasirox also carries many liver, kidney and blood-related contraindication signals, and these matter in people living with HIV who may already have such comorbidities.
To proceed, the following is needed:
- Mechanism of action data for deferasirox
- Preclinical studies directly testing deferasirox (not just iron status) on HIV replication, including the direction of effect
- Health Canada package insert warnings and contraindications for safety screening
- Review of interactions with antiretroviral regimens, which were not covered in the interaction data reviewed
- Evaluation of the other predicted indications (chronic hepatitis C, a rare neurodevelopmental disorder, obsolete familial combined hyperlipidemia, dermatofibrosarcoma protuberans), which currently have even weaker or only indirect support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.